A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay

Add time:07/25/2019    Source:sciencedirect.com

A new chiral synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (2, J-113397) was developed. J-113397 has a Ke = 0.85 nM in an ORL-1 calcium mobilization assay and is 89-, 887-, and 227-fold selective for the ORL-1 receptor relative to the μ, δ, and κ opioid receptors.

We also recommend Trading Suppliers and Manufacturers of 2H-Benzimidazol-2-one,1,3-dihydro-5-(hydroxymethyl)-(9CI) (cas 106429-58-7). Pls Click Website Link as below: cas 106429-58-7 suppliers

Prev:Interindividual Pharmacokinetics Variability of the α4β1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N′-(2-methylphenyl) ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl] methoxybenzoic Acid (D01-4582), in Beagles Is Associated with Albumin Genetic Polymorphisms
Next:Protic and substituted NCN palladium(II) pincer complexes with 1,3-bis(benzimidazol-2′-yl)-2-bromobenzenes: Structure and catalysis)